Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204327) titled 'Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)' on Sept. 24.

Study Type: Observational

Primary Sponsor: Zhongda Hospital

Condition: Unresectable Hepatocellular Carcinoma

Intervention: Other: Atezo+Bev plus Locoregional Therapy

Recruitment Status: Not recruiting

Date of First Enrollment: October 28, 2020

Target Sample Size: 1136

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07204327

Published by HT Digital Content Services with permission from Health Daily Digest....